Freshfields Bruckhaus Deringer is advising CVC Capital Partners, while Wachtell, Lipton, Rosen & Katz, Arthur Cox and A&O Shearman are serving as legal counsel to Mallinckrodt...
CVC Capital Partners’ $925 Million Acquisition of Therakos from Mallinckrodt
Novartis’ Licensing Agreement with Arvinas
Freshfields advised Novartis on its exclusive license agreement with Arvinas for a potential first-in-class prostate cancer treatment. Novartis, a global healthcare company, has entered into an...
Affibody AB’s License and Collaboration Agreement with Chiesi Farmaceutici S.p.A
Wiggin and Dana represented Affibody AB on the matter. Affibody AB has signed a collaboration and license agreement with Chiesi Farmaceutici S.p.A to discover, develop and commercialize innovative...
BioInvent’s Licensing Agreement with Exelixis
Wiggin and Dana LLP represented BioInvent International AB on the license agreement with Exelixis, Inc. to develop novel antibody-based immuno-oncology therapies. The collaboration is intended to...
Affibody AB’s License and Collaboration Agreement with ACELYRIN, INC.
Wiggin and Dana represented Affibody AB on the deal. Affibody AB signed a partnership agreement with ACELYRIN, INC. to develop and commercialize izokibep, a bispecific molecule targeting interleukin-17A...
Notable Labs, Inc.’s Acquisition of Development and Commercialization Rights to Volasertib
Wiggin and Dana represented Notable Labs, Inc. on the transaction. Notable Labs, Inc.), a pioneer and developer of predictive precision medicines, has obtained worldwide rights to...